Kopran

Kopran P/TBV

The Price to Tangible Book Value (P/TBV) of Kopran (KOPRAN.NS) as of Nov 16, 2026 is 1.18. In the previous year, Price to Tangible Book Value (P/TBV) was 1.24 — a change of -4.87% (lower).

P/TBV

1.18

YoY

-4.87%

Last updated:

Price to Tangible Book Value (P/TBV) of Kopran is 2025 1.18 . Price to Tangible Book Value (P/TBV) of Kopran was 2024 1.24 . It decreases by -4.87% lower compared to the previous year.

The Kopran P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2018
4.10 INR
Jan 1, 2019
3.61 INR
Jan 1, 2020
3.21 INR
Jan 1, 2021
2.46 INR
Jan 1, 2022
1.40 INR
Jan 1, 2023
1.38 INR
Jan 1, 2024
1.24 INR
Jan 1, 2025
1.18 INR
The Kopran P/TBV history
YEARP/TBVYoY
1.18-4.87%
1.24-9.90%
1.38-1.81%
1.40-43.13%
2.46-23.35%
3.21-11.06%
3.61-11.82%
4.10-13.36%
4.73-14.86%
5.55-14.17%
6.47+17.83%
5.49—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kopran Stock analysis

What does Kopran do? Kopran Ltd. generates revenue through the manufacturing and sale of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company produces penicillin-based finished oral dosage forms such as anti-infective, amoxycillin, ampicillin, cloxacillin, and amoxy clauv, as well as non-penicillin-based formulations including macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management, and gastroenterology products. Additionally, Kopran supplies APIs like anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems, and sterile cephalosporins. These products are sold to healthcare providers, distributors, and pharmaceutical companies seeking reliable sources of finished dosage forms and APIs for their own manufacturing processes. The company's product portfolio targets multiple therapeutic segments including anti-infective, cardiovascular, and gastrointestinal treatments. Its formulations cater to both penicillin and non-penicillin-based medical needs, while APIs support a broad range of pharmaceutical applications. Kopran's manufacturing focus on finished dosage forms and APIs enables it to serve the pharmaceutical industry's demand for essential drug components without direct consumer sales. Kopran Ltd. primarily serves pharmaceutical manufacturers and healthcare distributors who require high-quality active ingredients and finished drug products. The firm's production of capsules, injectables, and tablets ensures its offerings meet diverse market needs. By specializing in both formulation and API manufacturing, Kopran positions itself as a key supplier within the pharmaceutical supply chain, providing critical components for various medical treatments. Kopran is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kopran stock

Price to Tangible Book Value (P/TBV) of Kopran is 1.18 in 2025.

Price to Tangible Book Value (P/TBV) of Kopran changed from 1.24 to 1.18, representing a -4.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Kopran since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Kopran with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Kopran

All Key Metrics — Kopran